1. Up to Date on Which NOAC for Which Patient

3. Program Goals

4. In Clinical Trials, NOACs Have Demonstrated Favorable Efficacy and Safety Profiles vs VKAs

5. Attributes of NOACs

6. Decision Process for Selecting OAC Therapy: VKA vs NOAC

7. Contraindications for NOACs

8. All Major and Minor Bleeding Events on Warfarin

9. Recommendations From Taiwan AF Guidelines

10. Balancing Safety and Efficacy

11. Dose Reductions for NOACs

12. Canadian Dose Reduction Recommendation

13. ESC/EHRA Recommendation for Dose Reduction

14. Baseline Characteristics in AF Trials

15. Efficacy of Once-Daily NOACs vs Warfarin in AF Trials: Asian Subgroup

16. Reduction in All-Cause Mortality in Asians

17. GLORIA: Antithrombotic Therapy by CHA2DS2-VASc Score

18. Risk-Benefit Profile of NOACs vs Warfarin in the Elderly

19. Net Clinical Outcome of HDER (60/30 mg) in High-Risk Populations

20. Risk-Benefit Profile of NOACs vs Warfarin in the Elderly

21. Edoxaban vs Warfarin in Patients With an Increased Risk of Falls

22. Absolute Risk Reduction of Edoxaban vs Warfarin in Patients With an Increased Risk of Falls

23. Drug-Drug Interactions With NOACs

24. NOAC Administration: With or Without Food

25. ENSURE-AF: Study Design

26. Concomitant Use of Aspirin With OAC

27. Platelet -- All Trials

28. Efficacy of Edoxaban vs Warfarin in Patients With AF on Antiplatelet Therapy

29. Safety of Edoxaban vs Warfarin in Patients With AF on Antiplatelet Therapy

30. Risk of GI Bleeding

31. Which NOAC for Which Patient? Factors to Consider